Uterine fibroid embolization (UFE) is an effective, non-surgical method used to treat uterine fibroids in the fertile women population. It is performed with the help of uterine fibroid embolization agents, delivered to the tumor by micro-catheters.
Uterine Fibroid Embolization Agents Market is set to grow at a remarkable pace in the coming years. Uterine fibroids are benign growths in the uterus that can be asymptomatic and seen during the fertile period. Depending on the size and location of the fibroid in uterus, it can cause pain and heavy bleeding during menstrual cycle and affect the ability of a woman to conceive. The embolization agents block the arteries supplying blood to the tumor and force them to shrink. It is the most common form of tumor found in female reproductive system and therefore it is now one of the rising concerns amongst women. The increased awareness about the uterine fibroids amongst women and popularity of minimally invasive procedure will drive the global market for uterine fibroid embolization agents. In addition, the fact that UFE allows woman to preserve their uterus, otherwise not possible with full or even partial hysterectomy will further drive the market. Even though UFE is emerging as one of the most effective treatment available for UFE, side-effects such as infections, premature menopause, inflammation, and loss of menstrual periods can act as a barrier in the growth of the uterine fibroid embolization agents market.
Get the PDF brochure of this market insight @
The major players for uterine fibroid embolization agents are Astellas Pharma, Nippon Kayaku, Pfizer, Boston Scientific Corporation, Merit Medical Systems, Inc. and Cook Medical. As few companies are present in the market, acquisitions and collaborations were seen in the past. In November 2015, Boston Scientific Corporation acquired the interventional radiology segment of the CeloNova Biosciences (sole manufacturer of the PMMA microspheres in the world) to establish itself as the strongest player in the interventional oncology business.
UTERINE FIBROID EMBOLIZATION AGENTS MARKET SEGMENT:
- Gelatin Sponge
- Polyvinyl Alcohol (PVA) Particles
- Trisacryl Gelatin Microspheres (TAGM)
- Polymethyl Methacrylate (PMMA) Microspheres
- North America
- South Africa